Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells
To the Editor:
Chimeric antigen receptor transduced T cell (CART) therapy has demonstrated clinical activity in multiple malignant tumors. 1 In 2017, the United States Food and Drug Administration approved CD19-targeted CART cells (CARTs) as a salvage treatment for recurrent and/or refractory patients with B cell malignancies. 2, 3 In recent years, several CART clinical trials for multiple myeloma (MM) conducted worldwide have shown good clinical response, with target antigens including BCMA, CD19, and others. [4] [5] [6] [7] [8] [9] In addition to the clinical efficacy of CART therapy, it is important to pay attention to the possible adverse reactions, to reduce the severe, irreversible treatment-related mortality and to ensure that toxicity is managed well. Prolonged pancytopenia should also be a focus beyond unique acute cytokine release syndrome (CRS). 1 Such complications may bring the risk of fatal infection and bleeding, and could increase the hospital stay and economic burden of patients. Here, we report one patient with relapsed and refractory MM who developed bone marrow failure and severely prolonged pancytopenia after receiving sequential CD19and BCMA-specific CARTs. His hematopoiesis was successfully restored by the infusion of cryopreserved autologous stem cells.
Case presentation: A 41-year-old male was diagnosed multiple myeloma with IgG lambda in March 2018 after presenting with anemia, mildly elevated creatinine and multiple bone lesions. He received induction therapy with four cycles of bortezomib, thalidomide and dexamethasone (BTD), which resulted in maximum efficacy of partial remission according to the International Myeloma Working Group (IMWG) response criteria. 10 At this time, the patient was determined to have developed the complication of grade 2 peripheral neuropathy with pain. Autologous stem cells were collected after the administration of high-dose cyclophosphamide However, the response was poor, and the disease continued to progress.
In September 2018, high-dose conditional chemotherapy (busulfan 9.6 mg/m 2 and cyclophosphamide 3.6 g/m 2 ) was followed by salvage ASCT. The graft for ASCT was half the amount of the collection. The ASCT resulted in stable disease for 2 months. Considering this poor prognostic finding, the patient was later enrolled in the reported CART trial in our center in December 2017. 11 A bone marrow aspirate showed weak CD19 expression (0.08%) and strong positive BCMA expression (94.5%) on the clonal plasma cells by flow cytometry. The patient's treatment and administration schedule is shown in Figure 1A .
The patient presented a fever of 38.8°C ten hours after infusion of the first dose of CARTs-CD19, and the peak of temperature was 39.8°C on day two, and lasted for a total of 9 days. The peak serum ferritin level was also nearly four times higher compared to the baseline ( Figure 1B ).
Peak serum interleukin (IL)-6, IL-10 and interferon-γ levels were detected on day two postinfusion ( Figure 1C ). According to the guidelines of the CARTOX Working Group, 12 the patient had developed grade 3 CRS at this time. We treated the patient with a single 6 mg/kg dose of the IL-6R inhibitor tocilizumab. However, he continued to clinically deteriorate and experienced hypoxemia grade 1, elevated creatinine grade 2, elevated bilirubin grade 2, 13 and hypotension requiring support with a 0.40-0.45 μg/kg/min drop rate of norepinephrine. This toxicity culminated on day three post CART therapy. Methylprednisolone 2 mg/kg was administered to minimize the toxicity and to improve the patient's clinical symptoms. There was no neurologic toxicity. After IL-6R antibody and steroid administration, his cytokine levels, organ functions and clinical manifestations were dramatically ameliorated. On day eight postinfusion, we were able to discontinue the norepinephrine infusion ( Figure 1C ). Legend on next page.
CORRESPONDENCE E21
Note, CART therapy is associated with unique CRS toxicities.
Higher peak in vivo proliferation of CARTs is possibly associated with a clinical response, but it has also been associated with CRS grade. 3, 14, 15 Thus, CRS is an inflammatory syndrome caused by multiple cytokines produced by the CARTs themselves and by other cells, and can induce damage to multiple systems, including the hematopoietic system. 
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms
Mutations associated with chronic myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and
